-$0.06 Earnings Per Share Expected for Galectin Therapeutics Inc. (NASDAQ:GALT) This Quarter

Share on StockTwits

Equities research analysts expect Galectin Therapeutics Inc. (NASDAQ:GALT) to post earnings of ($0.06) per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Galectin Therapeutics’ earnings. Galectin Therapeutics reported earnings per share of ($0.08) in the same quarter last year, which would suggest a positive year-over-year growth rate of 25%. The firm is scheduled to issue its next earnings results on Wednesday, March 4th.

According to Zacks, analysts expect that Galectin Therapeutics will report full year earnings of ($0.35) per share for the current financial year. For the next year, analysts expect that the business will report earnings of ($0.41) per share, with EPS estimates ranging from ($0.51) to ($0.31). Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that follow Galectin Therapeutics.

Galectin Therapeutics (NASDAQ:GALT) last posted its earnings results on Tuesday, November 12th. The company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.03.

Separately, Zacks Investment Research cut shares of Galectin Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, November 18th.

In other news, major shareholder Fund L.P. 10X sold 17,000 shares of the stock in a transaction on Thursday, October 10th. The shares were sold at an average price of $3.73, for a total value of $63,410.00. The sale was disclosed in a filing with the SEC, which is available at this link. 40.70% of the stock is owned by insiders.

Hedge funds have recently modified their holdings of the stock. Vivaldi Capital Management LLC purchased a new position in Galectin Therapeutics during the 2nd quarter valued at $44,000. Squarepoint Ops LLC increased its stake in Galectin Therapeutics by 37.5% in the third quarter. Squarepoint Ops LLC now owns 13,901 shares of the company’s stock worth $51,000 after purchasing an additional 3,788 shares during the period. Commonwealth Equity Services LLC increased its stake in Galectin Therapeutics by 25.1% in the second quarter. Commonwealth Equity Services LLC now owns 15,247 shares of the company’s stock worth $63,000 after purchasing an additional 3,059 shares during the period. Centaurus Financial Inc. increased its stake in Galectin Therapeutics by 20,098.8% in the second quarter. Centaurus Financial Inc. now owns 16,563 shares of the company’s stock worth $69,000 after purchasing an additional 16,481 shares during the period. Finally, Amussen Hunsaker Associates LLC bought a new stake in shares of Galectin Therapeutics during the second quarter worth $71,000. 16.48% of the stock is owned by hedge funds and other institutional investors.

Galectin Therapeutics stock opened at $2.99 on Friday. Galectin Therapeutics has a 52-week low of $2.82 and a 52-week high of $6.06. The firm’s fifty day moving average is $3.58 and its 200 day moving average is $3.71. The company has a market cap of $170.09 million, a price-to-earnings ratio of -7.87 and a beta of 2.99.

Galectin Therapeutics Company Profile

Galectin Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, skin, and cancer diseases. The company's lead product candidate includes GR-MD-02 galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer.

Further Reading: Mutual funds are not immune from market timing

Get a free copy of the Zacks research report on Galectin Therapeutics (GALT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Galectin Therapeutics (NASDAQ:GALT)

Receive News & Ratings for Galectin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.